
Polar bear biopsies to shed light on Arctic pollutants
01 Jun 2025 06:00pm
Despite years of exposure, Svalbard's polar bears showed no signs of emaciation or ill health, according to the team. - AFP photo
NORWAY - With one foot braced on the helicopter's landing skid, a veterinarian lifted his air rifle, took aim and fired a tranquiliser dart at a polar bear.
The predator bolted but soon slumped into the snowdrifts, its broad frame motionless beneath the Arctic sky. Belgian toxicologist Laura Pirard works on biopsy samples of polar bear adipose tissue in a laboratory onboard the science icebreaker vessel Kronprins Haakon in the Svalbard archipelago. - AFP photo
The dramatic pursuit formed part of a pioneering research mission in Norway's Svalbard archipelago, where scientists, for the first time, took fat tissue biopsies from polar bears to study the impact of pollutants on their health.
The expedition came at a time when the Arctic region was warming at four times the global average, putting mounting pressure on the iconic predators as their sea-ice habitat shrank.
"The idea is to show as accurately as possible how the bears live in the wild -- but in a lab," Laura Pirard, a Belgian toxicologist, told AFP.
"To do this, we take their (fatty) tissue, cut it in very thin slices and expose it to the stresses they face, in other words pollutants and stress hormones," said Pirard, who developed the method.
Moments after the bear collapsed, the chopper circled back and landed. Researchers spilled out, boots crunching on the snow.
One knelt by the bear's flank, cutting thin strips of fatty tissue. Another drew blood.
Each sample was sealed and labelled before the bear was fitted with a satellite collar.
Scientists said that while the study monitors all the bears, only females were tracked with GPS collars as their necks are smaller than their heads -- unlike males, who cannot keep a collar on for more than a few minutes.
Arctic lab
For the scientists aboard the Norwegian Polar Institute's research vessel Kronprins Haakon, these fleeting encounters were the culmination of months of planning and decades of Arctic fieldwork.
In a makeshift lab on the icebreaker, samples remained usable for several days, subjected to controlled doses of pollutants and hormones before being frozen for further analysis back on land.
Each tissue fragment gave Pirard and her colleagues insight into the health of an animal that spent much of its life on sea ice.
Analysis of the fat samples showed that the main pollutants present were per- and polyfluoroalkyl substances (PFAS) -- synthetic chemicals used in industry and consumer goods that linger in the environment for decades.
Despite years of exposure, Svalbard's polar bears showed no signs of emaciation or ill health, according to the team.
The local population has remained stable or even increased slightly, unlike parts of Canada, where the Western Hudson Bay group declined by 27 percent between 2016 and 2021, from 842 to 618 bears, according to a government aerial survey.
Other populations in the Canadian Arctic, including the Southern Beaufort Sea, have also shown long-term declines linked to reduced prey access and longer ice-free seasons.
Scientists estimate there are around 300 polar bears in the Svalbard archipelago and roughly 2,000 in the broader region stretching from the North Pole to the Barents Sea.
The team found no direct link between sea ice loss and higher concentrations of pollutants in Svalbard's bears. Instead, differences in pollutant levels came down to the bears' diet.
Two types of bears -- sedentary and pelagic -- feed on different prey, leading to different chemicals building up in their bodies.
Changing diet
With reduced sea ice, the bears' diets have already started shifting, researchers said. These behavioural adaptations appeared to help maintain the population's health.
"They still hunt seals but they also take reindeer (and) eggs. They even eat grass (seaweed), even though that has no energy for them," Jon Aars, the head of the Svalbard polar bear programme, told AFP.
"If they have very little sea ice, they necessarily need to be on land," he said, adding that they spend "much more time on land than they used to... 20 or 30 years ago".
This season alone, Aars and his team of marine toxicologists and spatial behaviour experts captured 53 bears, fitted 17 satellite collars, and tracked 10 mothers with cubs or yearlings.
"We had a good season," Aars said.
The team's innovations go beyond biopsies. Last year, they attached small "health log" cylinders to five females, recording their pulse and temperature.
Combined with GPS data, the devices offer a detailed record of how the bears roam, how they rest and what they endure.
Polar bears were once hunted freely across Svalbard but since an international protection agreement in 1976, the population here has slowly recovered.
The team's findings may help explain how the bears' world is changing, and at an alarming rate.
As the light faded and the icebreaker's engines hummed against the vast silence, the team packed away their tools, leaving the Arctic wilderness to its inhabitants. - AFP
More Like This

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
4 hours ago
- The Star
Chikungunya cases on the rise
Cases of chikungunya fever are rising in southern China, prompting local authorities to take measures to curb its spread. What is chikungunya? Chikungunya is caused by a virus that can be passed to humans by infected mosquitoes, with most cases occurring in Africa, Asia and the Americas. Symptoms include fever and joint pain, which may persist for some time. How serious is China's outbreak? More than 7,700 people in the southern province of Guangdong have been infected in recent weeks, according to an article by the China Association for Science and Technology. Most cases have occurred in the industrial centre of Foshan, where 2,770 people fell ill between July 27 and Aug 2, the provincial disease control office said on Sunday. Dozens of infections have also been detected in neighbouring Guangzhou, while Hong Kong reported its first case on Saturday. Should people be worried? The United States has issued a travel advisory urging increased caution when going to affected areas in China. Some of China's prevention measures evoke its pandemic strategy, but comparisons to are overblown. Unlike Covid, chikungunya is caused by a known pathogen, and is not transmitted via human contact and very rarely proves fatal. — AFP


The Star
15 hours ago
- The Star
Weight rebounds quickly after stopping anti-obesity jabs
GLP-1 receptor agonists, which form the recent popular weight-loss medications, make you feel full for longer, but the effect appears to wear off rather quickly once the drugs are stopped. — AFP Doctors around the world have been hailing recent 'miracle' medications that make weight loss far easier, but new research suggests that after a person stops taking some of these drugs, the weight tends to increase again rather quickly. People who received these medications lost significant weight during the therapy, and this even continued to a small extent for a few weeks after stopping the drugs, according to a research team led by Dr Wu Han and Dr Yang Wenjia from the Peking University People's Hospital in Beijing, China. However, from the eighth week after the end of therapy, the researchers said that there was a marked weight gain that persisted for many weeks. The extent of weight gain varies depending on the medication and lifestyle changes, according to the study, but there is a clear trend towards weight gain after stopping the drugs. This confirms existing findings, according to Association of Catholic Clinics chief physician for diabetology and West German Diabetes and Health Centre director Dr Stephan Martin in Dusseldorf, Germany. He said that some manufacturers of the medications had also demonstrated this themselves through randomised studies. Test subjects in the studies were given the active substances for 10 weeks, after which some were switched to a placebo. This group 'then continuously regained weight', Dr Martin reported. ALSO READ: Stop the drugs and regain the weight In the current study, the Chinese researchers also referred to an investigation in which people who had completed a 36-week treatment with the active substance tirzepatide (a GLP-1 receptor agonist) regained about half of the weight they had previously lost within a year of switching to a placebo. The newly-published meta-analysis summarised the results of 11 independent studies from around the world, including those on the drug orlistat, the combinations naltrexone/bupropion and phentermine/topiramate, as well as the group of GLP-1 receptor agonists. The data came from a total of 1,574 people in treatment groups and 893 in control groups. GLP-1 receptor agonists are included in the recent popular anti-obesity medications. In some countries, they are approved for type 2 diabetes and some cases of obesity, and they are known as lifestyle drugs for achieving a slim figure. These active substances, which are injected regularly, primarily prolong the time food stays in the digestive tract, thereby increasing the feeling of satiety. Side effects include gastrointestinal complaints. One aspect of the study stands out: Those who initially experienced significant weight loss during therapy tended to regain more weight afterwards, even if they participated in programmes to change their lifestyle, such as eating and exercise habits. 'This does not surprise me,' says professor of behavioural medicine Dr Anja Hilbert at Germany's Leipzig University Hospital. Similar experiences are seen, for example, in people who follow a very low-calorie diet – they also tend to regain more weight after the diet ends than those who undergo moderate calorie limits. However, Prof Hilbert noted that there were only a few participants for this aspect of the study. 'The results of the study actually suggest that long-term, perhaps even lifelong use of the medication may be necessary to stabilise weight,' she says. 'It is a long-term therapy,' Dr Martin emphasises. Anyone who believes they can lose weight with this therapy and then everything will be fine is mistaken. 'You need this therapy permanently,' he says. Some in the American healthcare system have raised concerns that many people may be unaware of this or may not accept it. According to studies, two-thirds of people treated for obesity – most of whom pay for the treatment themselves – stopped using the medication within a year. 'We don't know why: Maybe it becomes too expensive, maybe they have lost enough weight and believe it will now stay off,' says Dr Martin, who advocates for more overweight prevention rather than treating the consequences. – By Simone Andrea Mayer/dpa


New Straits Times
19 hours ago
- New Straits Times
Ozempic maker's US$4.1bil profit hit by copycat rivals
COPENHAGEN: Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and Wegovy in the United States. The group reported a net profit of 26.5 billion kroner (US$4.1 billion), a 32 per cent increase from the same period last year, while sales increased by 18 per cent to 76 billion kroner. The drug maker lowered its annual earnings outlook last week, causing its share price to continue its nearly year-long slide. The company had already cut its forecast in May and announced the departure of its chief executive Lars Fruergaard Jorgensen. "In May we mostly thought the bottom was reached," Mikael Bak, director of the Danish shareholders' association, told AFP. Bak said "every is a bit surprised" that the situation has deteriorated. "So now we don't want to see more disappointments, there are reasons to believe the business is healthy, the institution and the products good," he said. Novo Nordisk announced last week that it was promoting Maziar Mike Doustdar, its vice president for international operations, to succeed Jorgensen. The popularity of Novo Nordisk's weight-loss treatments had once made it a darling of investors, boosting its share price and at one point making it Europe's most valuable company. But it now faces growing competition from rival treatments made by US group Eli Lilly in United States. A rule by the US Food and Drug Administration allowing pharmacies to create so-called "compound" copycat versions of the drug, after high demand led to shortages, has also dented Novo Nordisk's earnings.--AFP